FDA evaluates reports of suicidal thoughts or actions in patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
January 11, 2024 - The FDA announced results from a preliminary evaluation did not show a causal link between suicidal thoughts or actions in patients treated with GLP-1 RAs.
Top